Kyntra Bio announced its Q1 2026 financial results, showing steady progress in its drug pipeline. The Phase 2 trial of FG-3246 for metastatic castration-resistant prostate cancer is enrolling well, with interim analysis expected in Q4 2026. Positive Phase 1b/2 combination study results support the ongoing trial design. The company is finalizing the Phase 3 trial protocol for roxadustat to treat anemia in lower-risk myelodysplastic syndromes, aiming to start the trial in the second half of 2026. Kyntra Bio holds $100.3 million in cash and equivalents, funding operations into 2028.
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
